ストックスクリーナーアプリを入手
9.61
3.22%
-0.32
前日終値:
$9.93
開ける：
$9.95
24時間の取引高:
1.16M
Relative Volume:
0.83
時価総額：
$701.41M
収益：
-
当期純損益:
$-86.60M
株価収益率:
-3.3929
EPS:
-2.8324
ネットキャッシュフロー:
$-67.37M
1週間 パフォーマンス:
-6.24%
1か月 パフォーマンス:
+15.50%
6か月 パフォーマンス:
+119.41%
1年 パフォーマンス:
+44.08%
1日の値動き範囲:
$8.9301
$9.95
1週間の範囲:
$8.9301
$10.47
52週間の値動き範囲:
$1.45
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
名前
Lexeo Therapeutics Inc
セクター
電話
(212) 547-9879
住所
345 PARK AVENUE SOUTH, NEW YORK
LXEO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
9.61 | 724.76M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-18 | 開始されました | Raymond James | Strong Buy |
| 2025-11-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-10-15 | 開始されました | Guggenheim | Buy |
| 2025-07-31 | 開始されました | Oppenheimer | Outperform |
| 2024-06-13 | 開始されました | Robert W. Baird | Outperform |
| 2024-06-06 | 開始されました | H.C. Wainwright | Buy |
| 2023-11-28 | 開始されました | Chardan Capital Markets | Buy |
| 2023-11-28 | 開始されました | JP Morgan | Overweight |
| 2023-11-28 | 開始されました | Leerink Partners | Outperform |
| 2023-11-28 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-11-28 | 開始されました | Stifel | Buy |
すべてを表示
Lexeo Therapeutics Inc (LXEO) 最新ニュース
Contrasting Lexeo Therapeutics (NASDAQ:LXEO) and Wellgistics Health (NASDAQ:WGRX) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Wall Street Rallies Behind Lexeo Therapeutics (LXEO)’s Gene Therapy Pipeline - Insider Monkey
Lexeo Therapeutics CEO R. Nolan Townsend to Present at J.P. Morgan Healthcare Conference 2026 in San Francisco - Quiver Quantitative
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Lexeo Therapeutics, Inc.(NasdaqGM:LXEO) added to S&P Biotechnology Select Industry Index - marketscreener.com
What dividend safety score for Lexeo Therapeutics Inc. stockGap Down & Low Drawdown Trading Strategies - Улправда
Why Lexeo Therapeutics Inc. stock is a must watch in 2025Trade Entry Report & Long-Term Growth Portfolio Plans - Улправда
Why Lexeo Therapeutics Inc stock is a must watch in 2025Quarterly Risk Review & High Conviction Buy Zone Alerts - moha.gov.vn
Is Lexeo Therapeutics Inc. stock near bottom after declineTrade Risk Report & High Accuracy Investment Signals - Улправда
Lexeo Therapeutics Earnings Notes - Trefis
Will Lexeo Therapeutics Inc. stock deliver shareholder valuePortfolio Profit Report & High Accuracy Trade Alerts - Улправда
Dow Update: Can Lexeo Therapeutics Inc. stock resist sector downturnsJuly 2025 PostEarnings & High Win Rate Trade Tips - Улправда
Bearish Setup: Is Lexeo Therapeutics Inc. stock near bottom after declineMarket Weekly Review & Risk Controlled Swing Alerts - ulpravda.ru
Can Lexeo Therapeutics Inc. stock resist sector downturnsJuly 2025 News Drivers & Real-Time Stock Price Movement Reports - Улправда
Raymond James Initiates Coverage on Lexeo Therapeutics With Strong Buy Rating, $25 Price Target - marketscreener.com
This Valvoline Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Raymond James Initiates Coverage of Lexeo Therapeutics (LXEO) with Strong Buy Recommendation - Nasdaq
Raymond James initiates Lexeo Therapeutics stock with Strong Buy rating By Investing.com - Investing.com Canada
Biotech Momentum Carries After-Hours Trading Gains - RTTNews
Certain Pre-Funded Warrants of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-DEC-2025. - marketscreener.com
Certain Warrants of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-DEC-2025. - marketscreener.com
Certain Options of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-DEC-2025. - marketscreener.com
54,001,214 Common Stock of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-DEC-2025. - marketscreener.com
Janus Henderson Group PLC Expands Stake in Lexeo Therapeutics Inc - GuruFocus
Aug Wrap: Will Lexeo Therapeutics Inc stock benefit from AI adoptionStock Surge & Smart Allocation Stock Reports - moha.gov.vn
Lexeo Therapeutics (NASDAQ:LXEO) Receives “Buy” Rating from Chardan Capital - Defense World
Aug Action: What sentiment indicators say about Lexeo Therapeutics Inc stock - moha.gov.vn
Chardan Capital Maintains Lexeo Therapeutics (LXEO) Buy Recommendation - Nasdaq
Lexeo Therapeutics' (LXEO) Buy Rating Reaffirmed at Chardan Capital - MarketBeat
Lexeo Therapeutics (LXEO) Rating Maintained as 'Buy' by Chardan Capital | LXEO Stock News - GuruFocus
Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock By Investing.com - Investing.com Canada
Lexeo Therapeutics stock holds Overweight rating as Cantor sees PKP2-ACM potential - Investing.com Canada
Check Out Lexeo Therapeutics Inc (LXEO)’s Trade Data Rather Than the Analysts’ Views - setenews.com
Update Recap: Will Lexeo Therapeutics Inc stock benefit from AI adoptionJuly 2025 Fed Impact & Consistent Growth Equity Picks - moha.gov.vn
Transcript : Lexeo Therapeutics, Inc.Special Call - marketscreener.com
Portfolio Update: Why Lexeo Therapeutics Inc stock remains resilientJuly 2025 Review & Real-Time Buy Signal Notifications - moha.gov.vn
How resilient is Lexeo Therapeutics Inc. stock in market downturnsTreasury Yields & Fast Entry High Yield Stock Tips - Newser
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum - marketscreener.com
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event - GlobeNewswire
Why Lexeo Therapeutics Inc. stock remains resilientWeekly Stock Summary & Accurate Buy Signal Alerts - Newser
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Trading Down 7.8%What's Next? - MarketBeat
A look into Lexeo Therapeutics Inc (LXEO)’s deeper side - setenews.com
Lexeo Therapeutics (NASDAQ:LXEO) Now Covered by Analysts at Cantor Fitzgerald - MarketBeat
Lexeo Therapeutics stock undervalued, Cantor Fitzgerald reiterates $19 target By Investing.com - Investing.com Canada
Paradigm Biocapital Advisors LP Acquires Significant Stake in Le - GuruFocus
LXEO Stock Price and Chart — NASDAQ:LXEO - TradingView
Research Analysts Set Expectations for LXEO FY2025 Earnings - Defense World
Savant Capital LLC Invests $119,000 in Lexeo Therapeutics, Inc. $LXEO - MarketBeat
Lexeo Therapeutics Inc (LXEO) 財務データ
収益
当期純利益
現金流量
EPS
Lexeo Therapeutics Inc (LXEO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Adler Eric | Chief Medical Officer |
Nov 18 '25 |
Sale |
9.27 |
615 |
5,701 |
72,646 |
| See Tai Sandi | Chief Development Officer |
Nov 18 '25 |
Sale |
9.27 |
386 |
3,578 |
65,476 |
| Robertson Jenny | Chief Legal Officer |
Nov 18 '25 |
Sale |
9.27 |
549 |
5,089 |
68,381 |
| Otero Jose Manuel | Chief Technical Officer |
Aug 18 '25 |
Sale |
9.27 |
721 |
6,684 |
63,476 |
0.57%
大文字化:
|
ボリューム (24 時間):